
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934

Lixte Biotechnology Holdings, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

539319-10-3
(CUSIP Number)

David L. Ficksman, Esq.
1801 Century Park East, Suite 1600
Los Angeles, California 90067
310-789-1290

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 4, 2015
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [].

1. Name of reporting person: John Kovach

2. Check the appropriate box if a member of a group (*See* instructions):

(a)

(b)

3. SEC use only:

4. Source of funds: OO *See* Instructions

5. Check if disclosure of legal proceedings is required pursuant to Items 2(d) or (d):

6. Citizenship or place or organization: United States

Number of shares beneficially owned by each reporting person with:

7. Sole voting power: 9,021,789 shares of Common Stock

8. Shared voting power:

9. Sole dispositive power: 9,021,789 shares of Common Stock

10. Shared dispositive power:

11. Aggregate amount beneficially owned by each reporting person:

9,021,789 shares of Common Stock

12. Check if the aggregate amount in row 11, above, excludes certain shares (*See* Instructions):

13. Percent of class represented by amount in row 11, above:

19.25%

14. Type of reporting person (*See* Instructions):

IN

ITEM 1. SECURITY AND ISSUER

Common Stock
Lixte Biotechnology Holdings, Inc.
248 Route 25A, No. 2
East Setauket, New York 11733

ITEM 2. IDENTITY AND BACKGROUND

This statement is being filed by John Kovach (the “Reporting Person”). The Reporting Person is the Issuer’s Chief Executive Officer, President and a director. The principal business address for the Reporting Person is 248 Route 25A, No. 2, East Setauket, New York 11733. During the past five years, the Reporting Person has not been convicted in a criminal proceeding nor has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result, of which the Reporting Person was or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. The Reporting Person is a United States citizen.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The shares of the Issuer beneficially owned by the Reporting Person were originally issued in connection with and as the merger consideration pursuant to the merger of Lixte Biotechnology, Inc. (“LBI”) into the Issuer. The Reporting Person was a shareholder of LBI.

ITEM 4. PURPOSE OF TRANSACTION

On August 4, 2015, the Reporting Person contributed 8,000,000 shares to the John and Barbara 2015 Trust leaving the Reporting Persons with 9,021,786 shares.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Reference is made to the disclosure set forth under Items 1 and 3 of this Schedule 13D.

As of August 4, 2015, the Reporting Person owns directly 9,021,786 shares of Common Stock. Based on 46,875,814 shares of Common Stock outstanding, as of June 30, 2015 the Reporting Person beneficially owns approximately 19.25% of the shares of Common Stock outstanding.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

None.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 5, 2015

/s/ JOHN KOVACH

John Kovach
